Microbiological profile of community-acquired pneumonia in adults over the last 20 years

Howard, Luke; Sillis, Margaret; Pasteur, Mark C.; Kamath, Ajay; Harrison, B. D. W.

doi:10.1016/j.jinf.2004.05.003

Cited by 68 publications

(63 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of 10 recent studies including .250 patients, six did not find any cases due to PA [6,7,16,17,24,25], and the incidence in the remaining four was only 1-5% [4,21,26,27]. Likewise, in severe CAP, the incidence was higher, reaching 12% [19].…”

Section: Respiratory Infections and Tuberculosis H Von Baum Et Almentioning

confidence: 96%

Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors

Baum¹,

Welte²,

Marre³

et al. 2009

European Respiratory Journal

132

View full text Add to dashboard Cite

The aim of the present study was to determine the relevance of the presence of Enterobacteriaceae (EB) and Pseudomonas aeruginosa (PA) in patients with community-acquired pneumonia (CAP) and how the true incidence of these pathogens can be assessed.Based on prospective data from 5,130 patients with CAP included in the German Competence Network for Community-Acquired Pneumonia (CAPNETZ), the incidence, clinical characteristics, outcome and predictors of patients with CAP due to EB and PA were studied applying strict case definitions.The incidence of EB was 67 (1.3%) out of 5,130, including 27 patients with bacteraemia. PA was found in 22 (0.4%) out of 5,130 patients. These microorganisms were judged to be indeterminate pathogens in an additional 172 and 27 isolates, respectively. Patients with indeterminate pathogens differed considerably from those with definite isolates in terms of clinical presentation, comorbidity, pneumonia severity and outcome. Independent risk factors for EB included cardiac and cerebrovascular disease, and for PA chronic respiratory disease and enteral tube feeding. The 30-day mortality was significantly higher in patients with definite pathogens.In the present large population, the incidence of CAP due to EB/ PA was low. The risk of the presence of these pathogens can be assessed using several predictors, which may identify those patients in need of an extended diagnostic work-up and initial antimicrobial treatment.

show abstract

Section: Respiratory Infections and Tuberculosis H Von Baum Et Almentioning

confidence: 96%

Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors

Baum¹,

Welte²,

Marre³

et al. 2009

European Respiratory Journal

132

View full text Add to dashboard Cite

show abstract

“…7,24 There are other data showing that etiology can be confirmed in 29-75.6% of cases. 7,13,15,25,26 In our set up, the yield is low because of lack of facilities like PCR, detection of pneumococcal antigen in urine samples and serological tests like IgG ELISA for the confirmation of etiology. However the yield in our study is even lower than the studies conducted in similar settings like in India.…”

Section: -17mentioning

confidence: 99%

Etiology and clinical profile of inpatients with Community acquired pneumonia in Manipal Teaching hospital, Pokhara, Nepal

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Despite vaccination efforts, Streptococcus pneumoniae continues to be the most common pathogen of community-acquired bacterial pneumonia (CABP) irrespective of age and geographical location (2)(3)(4). Morbidity and mortality remain unacceptably high in part due to increasing drug resistance and limited effective antimicrobial options.…”

mentioning

confidence: 99%

In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model

Lepak

Zhao

Marchillo

et al. 2017

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Omadacycline is a novel aminomethylcycline antibiotic in clinical development for community-acquired bacterial pneumonia (CABP). We used a neutropenic murine pneumonia infection model to characterize the in vivo pharmacodynamic activity of omadacycline against Streptococcus pneumoniae. Four strains with various phenotypic resistances to other antimicrobials, including tetracyclines, were utilized. Drug concentration measurements were performed in the plasma and epithelial lining fluid (ELF) after administration of 0.5, 2, 8, and 32 mg/kg. Pharmacokinetic parameters were calculated using a noncompartmental model and were linear over the dose range. Penetration into ELF ranged from 72 to 102%. Omadacycline demonstrated net cidal activity in relation to the initial burden against all four strains. The pharmacokinetic/pharmacodynamic index AUC/MIC correlated well with efficacy (R 2 ϭ 0.74).

show abstract

Microbiological profile of community-acquired pneumonia in adults over the last 20 years

Cited by 68 publications

References 33 publications

Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors

Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors

Etiology and clinical profile of inpatients with Community acquired pneumonia in Manipal Teaching hospital, Pokhara, Nepal

In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model

Contact Info

Product

Resources

About